Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT01229566

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Trygg Pharma, Inc. (from the registry)
Registry
  • NCT NCT01229566
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01229566. Randomized; quadruple masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
AKR-963
Lead sponsor
Trygg Pharma, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01229566
Content hash
ff0003977de3b05c26cbbe0565f78dcecfc2f55d4817402370ed3ef18748118c